In Brief This Week: SynapDx; Quidel; Med BioGene, Precision Therapeutics; CellHealth Institute | GenomeWeb

NEW YORK (GenomeWeb News) – SynapDx this week said that it has received a "significant investment" from The Kraft Group that will support ongoing clinical development of its molecular diagnostic test for autism spectrum disorder. Lexington, Mass.-based SynapDx didn't disclose the amount of the funding from Kraft.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.